Advertisement

Topics

Search Results for "Tingkatan Satu Sejarah Nota"

09:07 EDT 30th April 2016 | BioPortfolio

Matching Channels

None

Matching News

ValiRx raises £500,000 to progess cancer trial

ValiRx (LON:VAL) has raised £503,000 gross through a placing at 12p per to fund its drug development pipeline. ValiRx has one drug, VAL201, going through  phase I/II trials, and has made an ap...

ValiRx PLC targets US institutions with new appointment

ValiRx Plc (LON:VAL) has appointed a specialist investor relations firm to build its recognition among academic, clinical, and business leaders in the US.  Burns McClellan has already carried o...

ValiRx PLC to present at leading US cancer conference

Shares in ValiRx PLC (LON:VAL) rose 2% after the life sciences specialist said it would be presenting research data at a leading oncology get-together in the US next month. The American Association ...

ValiRx sets up in Boston to strengthen investor base

Cancer drug developer ValiRx (LON:VAL) has established a US operation in Cambridge, Massachusetts and beefed up its US advisory team.  The aim is to encourage interaction with academic, clinica...

ValiRx: Bioscience Innovation

In this interview, filmed during BioEurope 2008 in Madrid, Fintan Walton speaks with Satu Vainikka, CEO of ValiRx, an AIM listed biopharmaceutical company based in the UK. Focusing on epigenetics, Val...

ValiRx to collaborate on gene silencing tech

Drug developer ValiRx (LON:VAL) has signed a three-year collaboration agreement with Finnish contract research company Pharmatest to develop products using gene silencing platform GeneICE. No money ...

ValiRx to collaborate with Finnish group using gene silencing tech

Drug developer ValiRx (LON:VAL) has signed a three-year collaboration agreement with Finnish contract research company Pharmatest to develop products using gene silencing platform GeneICE. No money ...

Janssen Announces the Initiation of Two Studies Evaluating Daratumumab (DARZALEX®) and Atezolizumab in Multiple Myeloma and Solid Tumor

RARITAN, N.J., March 21, 2016 /PRNewswire/ -- Janssen Research & Development, LLC announced today it has entered into a clinical trial collaboration agreement with Genentech, a member of the ...

Matching PubMed Articles

Development of a Novel PET Tracer 18FAlF-NOTA-C6 Targeting MMP2 for Tumor Imaging.

The overexpression of gelatinases, that is, matrix metalloproteinase MMP2 and MMP9, has been associated with tumor progression, invasion, and metastasis. To image MMP2 in tumors, we developed a novel ...

Development and characterization of an αvβ6-specific diabody and a disulfide-stabilized αvβ6-specific cys-diabody.

This work describes the development and characterization of two antibody fragments that specifically target the αvβ6 integrin, a non-covalent diabody and a disulfide-stabilized cys-diabody. The diab...

The Influence of the Combination of Carboxylate and Phosphinate Pendant Arms in 1,4,7-Triazacyclononane-Based Chelators on Their 68Ga Labelling Properties.

In order to compare the coordination properties of 1,4,7-triazacyclononane (tacn) derivatives bearing varying numbers of phosphinic/carboxylic acid pendant groups towards 68Ga, 1,4,7-triazacyclononane...

EphA2 as a Diagnostic Imaging Target in Glioblastoma: A Positron Emission Tomography/Magnetic Resonance Imaging Study.

AbstractNoninvasive imaging is a critical technology for diagnosis, classification, and subsequent treatment planning for patients with glioblastoma. It has been shown that the EphA2 receptor tyrosine...

Synthesis and in vivo PET Imaging of Hyaluronan Conjugates of Oligonucleotides.

Synthesis for 68Ga-labelled 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA)-chelated oligonucleotide hyaluronan (HA) tetra- and hexasaccharide conjugates is described. A solid-supported technique ...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement